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4Drug-related infectious diseases in Europe
I Introduction and objective of this report
This report provides an update on infectious diseases 
related to drug use in Europe for the period up to June 
2015. The report covers both the EMCDDA Drug-related 
infectious diseases indicator, which collects data on the 
situation, as well as data on the responses in the area. It 
includes highlights and new findings discussed during the 
indicator’s annual expert meeting, held in Lisbon on 15–16 
June 2015. This two-day event offered a platform for 
discussion among experts from the 28 EU Member States, 
Norway and Turkey. EU agency partners, international 
organisations and countries not affiliated to the EMCDDA 
were also represented (1). Annual network meetings 
primarily aim to share and discuss the analysis of national 
and European data and new developments, and their 
(1)  Information on the meeting including the agenda, presentations and 
supporting documents is available at the DRID meeting webpage.
implications for actions and policy development. It should 
be noted that as the publication is, in part, based on the 
presentations to the meeting, some of the information 
presented here is necessarily preliminary. 
This report also draws on analysis of the information 
provided to the EMCDDA by the national focal points and 
their experts in the 2014 annual reporting exercise. The 
multi-indicator data set used in the analysis covers and 
integrates aspects of the epidemiology (prevalence of 
injection, prevalence of infections among drug users, 
notifications of newly diagnosed infections, harm, 
morbidity, outbreaks) and responses (prevention, infection 
testing, drug and infection treatments, and harm 
reduction).
Drug injection. The estimated number of people who 
inject illicit drugs is likely to be declining in certain parts 
of Europe. Heroin remains the main drug injected in 
most countries but new patterns of injecting drug use 
are emerging. Harm reduction and prevention of 
transition to injection remains a priority in order to 
reduce the incidence of blood-borne infections — HIV 
and viral hepatitis in particular — and also to prevent 
other harms (notably overdoses). 
Hepatitis C virus (HCV). People who inject drugs and 
those who have injected in the past are disproportionally 
affected. They probably constitute an important share of 
those now living with HCV in Europe. Among samples of 
people who inject drugs, HCV antibody prevalence is 
commonly in the range of 40 % to 80 %. Many of those 
who inject or have injected drugs are unaware of their 
HCV infection, which delays their chance to get 
counselling and treatment. Effective treatments are now 
available in Europe, but provision is low and slowly 
scaling-up. The main challenges are low levels of testing, 
high treatment costs and unclear referral and treatment 
pathways in many countries. Problems in many 
countries also remain related to insufficient staff training 
and poor service collaboration. 
HIV. The increase in the number of new HIV diagnoses 
notified in Europe in 2011–2012, which resulted from 
outbreaks in Greece and Romania, has halted and the 
total has dropped to pre-outbreak levels, with provisional 
figures for 2013 showing 1 458 newly reported cases 
attributed to injecting drug use. However, concerns still 
exist about the potential for new local outbreaks in some 
countries and among certain sub-populations. There is a 
need for continued vigilance. Evidence-based HIV 
prevention interventions, tailored to the local 
epidemiological context, and targeted at those most at 
risk, should be provided at sufficient levels in order to be 
effective. 
Bacterial infections. The spread of bacterial infections 
related to drug injection, through poor hygiene or 
contaminated drugs, remains a problem, with outbreaks 
continuing to occur. Outbreaks of wound botulism have 
recently been identified in Scotland and Norway. 
Examples of awareness-raising and prevention 
resources produced by outbreak control teams were 
shared and discussed among experts on drug-related 
infectious diseases. 
Injection of stimulants. The injection of cathinones and 
other new stimulant substances is often associated with 
a high frequency of injection (10 to 20 times per day). 
This increases the risk of transmission of HIV and 
hepatitis viruses if injection equipment is shared. The 
risk associated with injection of new psychoactive 
At a glance: a summary of key points
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I  Overview of the current situation: prevalence and trends in injecting, HIV and hepatitis C virus infections
I Signs of declining trends in injecting drug use
People who inject drugs are a key population affected by 
blood-borne viruses, in particular HIV, hepatitis C virus 
(HCV) and hepatitis B virus (HBV), as these infections can 
all be transmitted through the sharing of injection 
equipment and, to a lesser extent, through sexual contact.
The estimated prevalence of injecting drug use in the 
general population is generally low, varying between 
countries from less than one to more than nine cases per 
1 000 population aged 15–64 (Figure 1). Almost half (14) 
of the 30 countries reporting to the EMCDDA do not have 
recent estimates available. This represents a significant 
information gap in terms of monitoring both the situation 
and the burden of disease related to drug use in Europe. 
substances is illustrated in Hungary by the increase in 
the HCV prevalence among samples of stimulant users, 
and concerns have also been raised in Wales and 
Scotland (United Kingdom) and in Ireland. 
Drug users in prison. There are still major shortfalls with 
regard to meeting the needs of drug users in prison, 
particularly in the areas of prevention, testing and 
treatment of infectious diseases. The principle of 
equivalence of care between the prison and the 
community has still not been achieved in most 
countries.
Reduced harm reduction funding. Whereas there is 
evidence of on-going HIV and HCV transmission in some 
countries, concerns have been raised about cuts to 
health-related resources, with reports of decrease in 
provision of harm reduction services. In particular, 
recent reports about the closure of two needle and 
syringe programmes in Hungary and about reductions in 
the provision of syringes in other countries are worrying.
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FIGURE 1
Prevalence estimates of injecting drug use (2008–2013 data)
Methods: CR, capture–recapture; CM, combined method; TM, treatment multiplier; TP, truncated Poisson; OT, other; HM, HIV multiplier; MM, mortality 
multiplier. See also Appendix 1.
Source: Table PDU-1-2 in the 2015 Statistical Bulletin.
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However, available data from a recent analysis (EMCDDA, 
2015a) on trends in drug injection among those admitted to 
drug treatment in Europe between 2000 and 2011 
suggests that current drug injection, including its incidence, 
has declined in recent years in Europe. Some sub 
populations though (such as injectors of new psychoactive 
substances, image- and performance-enhancement drugs 
and stimulants) in some countries, may not have 
experienced this decline and injection may even have 
increased. While heroin remains overall the drug most 
frequently involved in drug injection, the share of other 
opioids or stimulants is increasing. Treatment demand data 
have limitations as they do not capture the most recent 
trends (e.g. new patterns of injecting drug use and new 
substances injected such as cathinones) and mostly cover 
problem opioid users. The data are also influenced by the 
long time lag typically reported by clients between their 
first use of the drug and their entry into treatment.
I  High levels of HCV infection among people who inject drugs
HCV infection is by far the most prevalent blood-borne 
virus infection among people who inject drugs. In Europe, 
most estimates of HCV antibody prevalence among this 
group fall between 40 % and 80 %. In five of the 10 
countries with national data, more than half of the injectors 
are infected (Figure 2). 
HCV antibody levels among national or local samples of 
people who inject drugs are available from 20 of the 30 
countries for 2012–13. There are further limitations in the 
available information, with some estimates covering only 
certain cities or regions within a country while others were 
carried out in specific settings 
For example, in Sweden the studies reported are on drug 
injectors in local prisons. In broader terms in this country, 
HCV prevalence among people who inject drugs has been 
found to be high (between 60 % and 80 %) in various 
studies conducted during the last 15 years. HCV continues 
to be the infection that most commonly affects people who 
inject drugs in Sweden. Of the 2 066 new cases of HCV 
infection notified in 2013, over one-third (769) were 
attributed to injecting drug use. Among young injectors 
(age 20–24 years), 34 new cases were notified, indicating 
likely recent on-going transmission.
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FIGURE 2
HCV antibody prevalence among people who inject drugs in the European Union, Norway and Turkey, from surveillance 
and local studies, 2012–13
Source: Table INF-111 in the Statistical Bulletin.
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The meeting confirmed the high HCV prevalence levels 
among people who inject drugs, with new data (2014) from 
Lithuania (HCV antibody prevalence 77 %) and from 
Poland (HCV antibody prevalence 65 %) completing the 
current European picture. The most recent (2014) HCV 
prevalence estimates showed increases in Hungary (from 
24 % to 49 %, see also Figure 4) and Slovakia (from 36 % to 
41 %), compared with previous estimates available. In 
Cyprus, a decrease was noted, from 48 % in 2013 to 43 % 
in 2014, although sample sizes were small. A large 
nationally representative sero-prevalence study in Norway 
documents high but decreasing levels of HCV infection 
among people who inject drugs, from 73 % in 2009 to 63 % 
in 2013.
The on-going transmission of HCV among people who 
inject drugs in Europe has also been observed in data on 
infections among young and among recent users. In half of 
the countries with available data, a quarter or more of the 
new injectors tested (those who report starting injecting 
within the last two years) were found to be infected (2).
I  New HIV diagnoses fall, but rates remain high in some countries
HIV is the other major viral infection disproportionally 
affecting people who inject drugs compared with the 
general population. Prevalence levels among people who 
inject drugs are overall much lower than those for HCV 
infection, typically below 5 %, but are much higher in 
countries with recent HIV outbreaks (Greece and 
Romania), in some Baltic and northern European countries 
(Estonia, Latvia and Poland) as well as in southwest 
Europe (Spain and Portugal), the latter being countries 
where HIV had entered injecting drug using populations 
very early, before prevention measures were put in 
place (3).
Provisional figures for 2013 show 1 458 newly reported 
cases attributed to injection drug use in the EU Member 
States, Norway and Turkey, compared with 1 974 in 2012. 
This reverses the upward trend seen since 2010. In 2013, 
the average rate of newly reported HIV diagnoses 
attributed to injecting drug use in these 30 countries was 
2.5 per million population, but considerable differences 
between the countries exist, for example in Estonia, this 
rate is 22 times higher than the 30-country average. 
Overall, the number of new HIV diagnoses attributed to 
injecting drug use in Europe has declined by more than a 
third over the past decade, (2004–2013) and transmission 
(2) See Table INF-113 in the 2015 Statistical Bulletin. 
(3) See Table INF-108 in the 2015 Statistical Bulletin. 
due to injecting drug use accounted for 5 % of HIV 
diagnoses in 2013 (ECDC and WHO, 2014). Against a 
background of an overall improving situation, evidence of 
strong increases in new infections, due to recent localised 
outbreaks in Greece and Romania in 2011 and 2012, can 
be seen (Figure 3).
I  Recent measures of HIV and HCV prevalence and risk in Estonia, Lithuania and Romania
HIV, HCV and responses indicators still point to reasons for 
concern in several countries (see Appendix 2).
The situation in three countries (Estonia, Lithuania and 
Romania) received particular attention at the meeting. In 
Estonia, the risk factors include a high prevalence of 
injecting drug use and of HIV infection (explained partly by 
fentanyl injection). Romania, which has experienced a 
major recent HIV outbreak, and although now reporting 
reduced numbers of new HIV cases (provisional data), is 
still facing difficulties in providing effective prevention 
responses, such as needle and syringe programmes, 
opioid substitution treatment and drug treatment provision 
in general. In Lithuania, the results from a new multisite 
study among people who inject drugs show that a majority 
of them had never been in contact with drug treatment and 
only 7.5 % were currently receiving opioid substitution 
treatment.
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Other countries
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FIGURE 3
Trends in number of newly diagnosed HIV cases in 
persons infected through injecting drug use in the 28 EU 
Member States, Norway and Turkey
Source: ECDC
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In 2014, Estonia reported a sharp decline at national level 
in newly reported HIV infections overall and among people 
who inject drugs, but the number of new HCV infections 
increased. A bio-behavioural survey conducted in 2014 
among 350 clients of needle and syringe programmes in 
the city of Narva, capturing a group of mainly male, 
Russian-speaking amphetamine (63 %) and fentanyl 
(27 %) current injectors, found that half were infected with 
HIV (prevalence of 48 %). Among the same sample, HCV 
prevalence was 61 %, which is however lower than the 
94 % HCV prevalence found among people who inject 
drugs in a local survey in the capital region. Prevalence of 
the hepatitis B surface antigen (HBsAg; indicating that the 
person is infectious) in the Narva study was 22 % and only 
a third (33 %) had ever been in drug treatment. Syringe 
provision in Estonia was scaled up between 2003 and 
2010 and has since remained on a high level: about 400 
syringes are given out per estimated drug injector per year 
in the country. The number of visits to needle and syringe 
programmes peaked in 2007 at 200 000, but is now 
declining. The decreasing number of clients reported by 
needle and syringe programmes may indicate that the 
injecting epidemic in Estonia is receding. The most recent 
estimate of injecting drug use in Estonia is of 5 360 
persons (5.9/1 000 adult population, range 4.3 to 10.8). 
Romania reported a total of 165 new cases of HIV among 
people who inject drugs for 2014, an improvement since 
the peak of the outbreak in 2012, when 252 cases were 
reported. Nonetheless, among the cases reported in 2014, 
almost half (82) had an AIDS diagnosis. The high 
proportion of AIDS diagnoses among newly reported HIV 
cases can suggest both late diagnosis and inadequate 
treatment. Co-infection was frequent among the newly 
reported HIV/AIDS cases (82 % with HCV, 22 % with 
tuberculosis, and 24 % with sexually transmitted diseases). 
Overall, heroin is still the primary drug injected, but 
intensive injecting patterns involving polydrug use of 
heroin and stimulants or new psychoactive substances are 
reported. High levels of syringe sharing (27 %) are also 
mentioned. Needle and syringe programmes tested 671 
clients for HIV and HCV — three times more than in 2012 
— of whom, 17 % tested positive for HIV and 43 % for HCV. 
However, HIV prevalence among those reached at drug 
treatment centres and those attending needle and syringe 
programmes in 2014 was lower than in the previous year. 
Due to a lack of funds, the overall response to the 2011 HIV 
outbreak among the estimated 6 000 people actively 
injecting drugs in Bucharest remains limited. Only 1 000 
drug users are estimated to receive drug treatment, and 
the number of clients visiting the three needle and syringe 
programmes (two fixed, one outreach) operating in the city 
fell from more than 5 100 to fewer than 2 700 in 2014, 
which was explained as possibly being related to increased 
police activities and incarcerations.
In Lithuania, there were 38 newly reported HIV infections 
in persons infected through injecting drug use in 2014, 
continuing the decrease observed since the peak in 2009 
(118 cases reported). A new bio-behavioural survey 
conducted at low-threshold agencies in three cities among 
a predominantly heroin-using group (200 respondents) 
found high prevalence levels of antibodies to HIV (12.5 %) 
and HCV (77 %) and HBsAg (10.5 %). More than three-
quarters of the sample had never been vaccinated against 
HBV. Lack of access to drug treatment (63 % had never 
been in treatment) and high levels of syringe-sharing 
behaviour indicate ongoing risk.
I  Cathinone injecting leading to adverse health consequences and potential increased infection risk in Hungary, Ireland and Wales 
The injection of stimulants, including new psychoactive 
substances such as cathinones, is often associated with a 
high frequency of injection (10 to 20 times per day). This 
increases the risk of viral and bacterial infections and of 
injecting-related injuries if injection equipment is shared or 
reused. Stimulants have also been linked with reduced 
sexual inhibition, and also associated with more risky 
drug-use and sexual behaviours. Increases in the numbers 
injecting cathinones have been reported in Hungary and 
been linked to increases in the HCV prevalence among 
samples of stimulant users. Concerns have also been 
raised about the injection of new psychoactive substances 
in Ireland and parts of the United Kingdom (Wales and 
Scotland).
In Hungary, over the last few years, there are concerns 
around changes in injecting drug use patterns. According 
to the 2014 national sero-prevalence study at drug 
treatment centres and needle and syringe programmes, 
half of the people currently injecting drugs now inject new 
psychoactive substances, and the prevalence of HCV 
among this group of injectors is 74 %. The overall 
prevalence of HCV among injecting drug users has 
increased since the previous survey in 2011, particularly 
among those injecting stimulants (Figure 4). Behavioural 
data from the same study show that half (48 %) of those 
currently injecting new psychoactive drugs reported 
sharing syringes, and 71 % reported sharing other 
equipment. Cathinones mentioned as being injected were 
mephedrone, pentedrone, MDPV and alpha-PVP (‘music’, 
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‘penta crystal’). The availability of harm reduction 
measures has decreased and is expected to decrease 
further in 2015 due to the closure of two needle and 
syringe programme sites in 2014. 
In Ireland, an increase in recently acquired HIV among 
people who inject drugs has been observed in Dublin since 
early 2015. The increase might be linked to injection of the 
synthetic cathinone alpha-PVP, street name Snow Blow, 
with the attendant consequences of more frequent 
injecting, and unsafe sexual and needle-sharing practices. 
This has mainly been seen in drug users who report 
polydrug use, and are often homeless. Fifteen confirmed 
cases of recently acquired HIV infection have been 
diagnosed in people who inject drugs in Dublin between 
June 2014 and June 2015. In 2013, the total number of 
newly reported infections related to drug injecting in 
Ireland was 18.
In Wales (United Kingdom), an increase was reported in the 
numbers of individuals accessing needle and syringe 
programmes with primary new psychoactive substance 
use. Injection of cathinones, particularly in the groin area 
has led to an increase in physical impacts: granular/gritty 
lumps under the skin, profound bruising, abscesses, deep 
vein thrombosis, long-term stays in intensive care units of 
up to 3 months, amputations, severe weight loss and 
requirement for major reconstructive surgery to femoral 
veins. Increased injection rates were also noted, going from 
approximately 3 up to 15–20 times per day. There are 
concerns also around the sharing of needles and unsafe 
sexual practices, and an increase in sexually transmitted 
infections among people who injected new psychoactive 
substances. Users reported that they chose injection 
because of the problems associated with other forms of 
administration: nose bleeds and intense pain from snorting, 
vomiting from oral ingestion. Those who injected in the 
groin area did so because it could be hidden, particularly 
because of the frequency of injection. Also noted among 
those moving to cathinone injection was a large increase in 
contact with criminal justice (i.e. related to mephedrone, 
including where individuals had no previous contact with 
criminal justice) and an increase in reported memory loss 
and incidents of violence and aggression.
Swansea, the second largest city in Wales and an area with 
a large opioid-injecting population, reported an increase in 
the prevalence of HCV among injecting drug users, from 
42 % in 2006 to 72 % in 2014. Unconfirmed HIV data 
highlighted new cases in people who inject drugs, and a 
particular risk was reported to be injection of mephedrone. 
Sexual health clinics, for instance, reported the first cluster 
of cases among people who inject drugs in 14 years. The 
responses in dealing with this trend of new psychoactive 
substance injection have included: information and 
awareness-raising campaigns; training, both e-learning and 
face to face for all staff; increased detection through 
proactive dried blood spot testing for blood-borne viruses 
in a range of settings including homeless centres and low 
threshold drug services; enhanced surveillance service; 
scaling up of injecting equipment provision (Figure 5); and 
research studies on the prevalence estimate of problematic 
and injecting drug use.
In Scotland, there have been recent concerns about the 
emergence of the injection of ethylphenidate.
FIGURE 4
HCV prevalence among people who have ever injected drugs, in total and by drug of choice, 2006–14, Hungary
NB: No data are available for the years 2010, 2012 and 2013. 
Source: Anna Tarjan. Presentation at the DRID 2015 annual expert meeting — available from the DRID meeting webpage.
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I  Wound botulism outbreaks and other bacterial infections
Bacterial infections among people who inject drugs, as 
result of either poor hygiene or the contaminated drugs 
continue to cause substantial harm. There has been a 
marked increase in the number of wound botulism cases 
among people who inject drugs, with a cluster in Scotland 
(United Kingdom) and another in Norway. In addition, 
reports from the United Kingdom and from Belgium 
highlight ongoing injection-related skin and soft-tissue 
infections among people who inject drugs, with these 
linked to ‘missed-hits’ and use of certain injection sites, 
such as the neck and groin, that are associated with 
increased risk of complication. 
In Scotland, the outbreak of wound botulism among 
people who inject drugs (December 2014 to June 2015) 
was the largest reported to date (47 cases, of which 17 
confirmed) (Figure 6). All cases presented with typical 
symptoms, but were not always recognised and diagnosed 
immediately. All received antitoxin and antibiotics. Just 
over half were ventilated and half had surgical 
debridement. The median age of the patients was 42 years 
(range 24–56) and 67 % were males. The source of 
infection remains unconfirmed, though it is likely to be 
associated with contaminated heroin or cutting agent. All 
cases reported involved heroin obtained either in, or 
sourced via, Glasgow. Risk communication was promptly 
initiated. It was aimed both at people who inject drugs and 
those working with them, and focused on recognising the 
symptoms of botulism and prompt healthcare seeking, 
leading to early diagnosis (4). 
Another outbreak was reported in Norway between 
November 2014 and early 2015. This was the subject of a 
joint EMCDDA–ECDC risk assessment released in 
February 2015 (EMCDDA and ECDC, 2015). At the time of 
the meeting, botulism testing on samples from people who 
inject drugs in Norway is done at the Statens Serum 
Institute in Copenhagen using the mice assay. The reason 
for this is reluctance by the Norwegian reference 
laboratory to inject mice with serum from drug users in 
case of needle stick injuries. The Norwegian Institute of 
Public Health are in the process of establishing alternative 
methods for diagnosis of botulism among this group of 
drug users. 
On 12 March 2015, in Germany, the Robert Koch Institute 
was notified of a case of wound botulism in a 34-year-old 
male who had injected heroin. He was hospitalised with a 
necrotic wound at the thigh and typical clinical symptoms 
of botulism (paralysis, ptosis, diplopia). Molecular testing 
confirmed the presence of botulinum neurotoxin B in the 
wound material.
(4)  Information posters and leaflets are available at the DRID meeting 
webpage.
FIGURE 5
Number of unique individuals accessing specialist and community pharmacy needle and syringe programmes reporting 
primary and any injecting use of new psychoactive substances in Wales, 2011–12 to 2014–15
NB: The term specialist needle and syringe programme refers to syringes and harm reduction advice provided by statutory (NHS) and voluntary drugs agencies.
The Harm Reduction Database Wales covers client data collected at community pharmacy needle and syringe programmes since April 2014. As such, data on 
unique individuals accessing pharmacy needle and syringe programmes are only available for the period 2014–15.
Source: Josie Smith. Presentation at the DRID 2015 annual expert meeting — available from the DRID meeting webpage.
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Two sporadic cases of wound botulism have also been 
reported recently in England (United Kingdom); one in 
2014 and one in 2015.
A recent study on injection practice among people who 
inject drugs in the United Kingdom found that although 
99 % reported that they aimed to inject intravenously, the 
majority (56 %) reported having ‘missed a hit’ — i.e. 
accidentally injected subcutaneously or intramuscularly. 
For a quarter (27 %), missed hits happened at least 
monthly. Missed hits were significantly associated with 
higher risks of abscesses (odds ratio 2.01), sore or open 
wounds (odds ratio 2.15) and appeared to be associated 
with poor injection practice. Interventions to improve 
injecting technique and hygiene and to help sustain 
access to the peripheral veins are needed. 
In Belgium, annual surveys conducted in needle and 
syringe programmes in the Flemish Community showed 
high frequency of injection in high-risk anatomical sites. In 
2014, 33 % of the 256 participants in the survey reported 
having ever injected in their neck and 25 % in their groin. 
History of injection abscesses was reported by almost 
40 % of those interviewed. In addition, a large minority 
FIGURE 6
Cases of probable and confirmed wound botulism among heroin users in Scotland (United Kingdom), December 2014 to 
June 2015. Age, gender, geographical distribution and information leaflets
Source: Gillian Penrice for the Outbreak Control Team. Presentation at the DRID 2015 annual expert meeting — available from the DRID meeting webpage.
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Between December 2014 
and June 2015 there were 
47 cases (17 con rmed)
of wound botulism
in Scotland
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(40 %) reported having injected while in a public place, 
which carries a higher risk of infection, due to hurriedness 
and lack of hygiene.
I  Scaling up HCV treatment for people who inject drugs in Europe
I  The drug-related infectious diseases network as a platform for sharing best practice
The combination of harm reduction measures such as 
opioid substitution treatment and needle and syringe 
programmes contribute to reducing the number of new 
infections, but it is unclear whether these measures would 
be sufficient on their own to lead to substantial reductions 
in HCV prevalence in all settings in Europe. The situation 
varies across Europe, due to the many factors that affect 
the spread of HCV among people who inject drugs. These 
include the size of the population at risk (Figure 1 and 
Appendix 1), the current prevalence of HCV infection 
(Figure 2) and the coverage of harm reduction measures 
(EMCDDA, 2015b, Chapter 3). 
In synergy with other interventions, the scaling-up of HCV 
treatment is likely to have a substantive impact through 
reducing the number of people with infection. There are 
advances in treatment options, including a new generation 
of medicines (EMCDDA, 2015c). This represents major 
opportunities and, at the same time, challenges to health 
systems, due to the very high prices of these medicines. 
For example, one course of treatment with Sofosbuvir 
costs between EUR 36 000 and EUR 48 000 in the eight 
countries that responded to an EMCDDA survey. Access to 
the treatment may be conditional in many countries, 
especially in those countries where the public spending on 
health has either decelerated or fallen recently, such as 
Greece, Latvia, Portugal and Ireland. In July 2014, a joint 
procurement agreement entered into force at EU level, 
which allows Member States to coordinate the purchase of 
medical countermeasures (5). Currently, joint 
procurements are being prepared for pandemic vaccines 
and personal protective equipment (relevant for highly 
infectious diseases like Ebola). Interest has been 
expressed by stakeholders in exploring the use of this 
mechanism for the purchase of HCV medications, but no 
concrete steps have yet been taken.
(5)  More information about the joint procurement is available on the DRID 
meeting webpage. 
There are good examples of integrated and multi-
disciplinary HCV treatment policies. In the Netherlands, for 
example, while a medical specialist is responsible for the 
treatment, the support from addiction care has been found 
indispensable throughout the care pathway, from case 
finding, preparation for HCV treatment, guidance and 
support during the medical treatment itself and during 
aftercare. Indeed, a main role of the addiction specialist 
has been to ‘clear’ the care pathway and successfully 
direct those in need of HCV treatment to the relevant 
providers (Care pathway: who is when responsible for 
what) (6). 
HCV treatment strategies and action plans that specifically 
address people who inject drugs exist in Austria, Denmark, 
France, Greece, Ireland, Lithuania, Norway, Slovenia and 
the United Kingdom (Maticic, 2014) and new initiatives 
were reported from Luxembourg and Portugal. The 
drug-related infectious disease network represents an 
important platform for sharing all these national 
developments.
I  Prison and responses to drug injection: still a long way to equivalence of care 
A history of drug use is common among European prisoners, 
with levels disproportionately high compared with the 
general population. Health problems, especially blood-borne 
and other communicable diseases and psychiatric co-
morbidity, are highly prevalent among prisoners with recent 
drug use or those who used drugs in the past. However, 
where studies have been conducted, major differences have 
been found between European countries in the prevalence 
of drug use and drug-related problems among prisoners. 
There are still major shortfalls with regard to meeting the 
health-related needs of drug users in prison, including the 
prevention, testing and treatment of infectious diseases. 
This was illustrated during the meeting by expert reports 
from Spain, Ireland, Latvia, the United Kingdom and other 
countries. Promising initiatives and changes such as the 
‘opt-out’ rule for HCV testing of prisoners are put in place, 
like in the United Kingdom, where full implementation of this 
measure is expected to be reached at the end of 2016. 
Within this framework, data from repeat testing of inmates 
will help gather information on and better respond to 
infection transmission in prison. 
The quick turnover of prisoners was pointed out by the 
experts as a challenge to the aim of offering systematic 
testing and follow-up planning. A large part of the prison 
population changes or leaves prison after a short period, 
which is often insufficient to plan interventions. Prison 
(6) See the video in Dutch available on Youtube.
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over-crowding and lack of continuity of care were identified 
as obstacles to good prison health in many countries. In 
European countries, valid and comparable data on drug 
use and related consequences among prisoners are still 
scarce and harmonisation work is needed. The principle of 
equivalence of care between the prison and the 
community has still not been achieved in most countries.
I  Drug-related infectious disease news and updates
US HIV outbreak. The US Centers for Disease Control and 
Prevention has issued a national health advisory in light of 
its investigation with the Indiana State Department of 
Health of a large outbreak of recent HIV infections among 
persons in Indiana who inject drugs. Many of the HIV-
infected individuals in this outbreak are co-infected with 
hepatitis C virus (link).
New drug consumption room in France. In April 2015, a 
six-year trial of drug consumption rooms was approved in 
France and final discussion will take place in September at 
the Senate. It is expected that facilities will be opened in 
the coming months in Paris, Bordeaux and Strasbourg. 
Drug consumption facilities provide users with clean 
injecting equipment, supervision of drug use and 
emergency care in the case of overdose. They are health 
facilities, staffed with counsellors and healthcare workers, 
whose tasks include ensuring improved access of clients 
to further care and treatment. Around 80 facilities are 
currently operating in seven European countries. See the 
EMCDDA website for more information on consumption 
rooms (link).
EU Joint Action on HIV and harm reduction starts. A new 
Joint Action on HIV and co-infection prevention and harm 
reduction, with the active participation of partners from 19 
EU countries and co-funded under the EU health 
programme 2014–2020 with EUR 3 million will start in 
autumn 2015. The 3-year project brings together 26 
associated and affiliated partner organisations in actions 
to further limit the spread of infectious diseases among 
people who inject drugs in Europe and will have a special 
focus on Latvia, Lithuania and Hungary as countries 
showing specific risk contexts and deficiencies in the 
response (link).
WHO European consultation takes place. A regional 
consultation on the WHO Global Health Sector strategies 
2016–2021 on sexually transmitted infections, HIV and 
viral hepatitis was held at the Regional Office in 
Copenhagen (23–26 June 2015) with participation of 
national focal points from Europe and central Asia, partner 
organisations and civil society. Giving renewed attention to 
health problems that still play an important role for people 
who inject drugs in the European region, the three 
strategies are being prepared for adoption by the 69th 
World Health Assembly in May 2016 (link). 
EC call for applications launched. Under the third 
programme of the Union’s action in the field of health 
(2014–2020), a call for applications for projects on ‘early 
diagnosis and treatment of viral hepatitis’ was published 
by the European Commission on 5 June 2015. All relevant 
information on the call, the selection, award and other 
criteria for financial contributions are available on the 
website of the Consumers, Health, Agriculture and Food 
Executive Agency (Chafea) at ec.europa.eu/chafea/. The 
submission deadline was 15 September 2015 (link). 
New report launched on injecting drug use trends. A new 
EMCDDA report, Estimating trends in injecting drug use in 
Europe using national data on drug treatment admissions, 
was launched in June. The report found that the incidence 
and prevalence of current drug injection has declined in 
recent years in Europe. While heroin remains the drug 
most frequently involved in drug injection, drug injectors 
are now more likely to be using stimulants than in the past. 
The report is available online (link).
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I Appendixes
I Appendix 1
Estimates of the prevalence of injecting drug use (rate per 1 000 population aged 15–64), last study available
Rate (per 1 000 population aged 15–64) Estimated number of users
Country Year Central Lower Upper Central estimate Lower bound Upper bound 
Belgium 2013 3.54 2.5 4.82 25 673 18 135 34 987
Croatia 2012 0.44 0.35 0.61 1274 998 1 746
Cyprus 2013 0.29 0.2 0.46 177 128 282
Czech Republic 2013 5.98 5.94 6 42 700 42 450 42 900
Estonia 2009 5.89 4.29 10.8 5 362 3 906 9 837
Finland 2012 4.6 4.1 6.7 15 611 13 770 22 665
Greece 2013 0.73 0.62 0.88 5 284 4 451 6 338
Hungary 2008–09 0.82 56 99
Latvia 2012 9.22 7.34 11.68 12 573 10 003 15 914
Luxembourg 2009 5.68 4.5 6.85 1 907 1 524 2 301
Netherlands 2008 0.22 0.21 0.22 2 390 2 336 2 444
Norway 2012 2.52 2.15 3.04 8 393 7 159 10 141
Spain 2012 0.38 0.3 0.44 11 865 9 669 14 061
United Kingdom 2004–11 3 2.87 3.22 122 894 117 370 131 869
NB: The estimates are based on several sources and statistical methods (e.g. capture–recapture, mortality multiplier) and not only on treatment data. They may 
underestimate the prevalence of injection, as some substances may not appear in the sources used (e.g. these estimates will not include image and perfor-
mance enhancing drugs). Caution is required when comparing countries. More information is available from http://www.emcdda.europa.eu/activities/hrdu 
Source: Statistical Bulletin 2015 http://www.emcdda.europa.eu/data/stats2015#displayTable:PDU-1-2
16
Drug-related infectious diseases in Europe
I Appendix 2
Risk assessment — supplementary table. Indicators of HIV notification trend, HIV and HCV prevalence estimates, 
transmission risk and prevention coverage in 30 European countries
Country
HIV-related indicators Indicators of transmission risk Intervention coverage indicators
HIV case  
trend (i)
HIV  
prevalence  
trend
HCV prevalence  
increasing or high 
HCV prevalence 
Injecting drug use 
prevalence 
increasing or high
Problem opioid 
users in 
substitution 
treatment (%) (ii)
Syringes 
distributed by 
specialised 
programmes 
(per injecting 
drug user 
per year) (iii)
Austria 60
Belgium 23
Bulgaria
Croatia 41 215
Cyprus 19 0
Czech Republic 34 145
Denmark
Estonia 407
Finland 226
France 80 
Germany 46 
Greece 62 81
Hungary 24 76
Ireland 41
Italy 56
Latvia 4 27
Lithuania 11
Luxembourg 65 101
Malta 54
Netherlands 58
Norway >50 359
Poland 11
Portugal
Romania
Slovakia 8
Slovenia 47
Spain >50 226
Sweden
Turkey
United Kingdom 45
None of the following risk factors identified: increase in HIV case reports or prevalence of HIV or HCV; increase in 
transmission risk; low intervention coverage.
Risk factors possibly present: HIV or HCV prevalence or transmission risk showing increase at subnational level or 
consistent but non-significant increase at national level.
Risk factor present: significant increase in HIV case reports or HIV or HCV prevalence; increase in transmission risk; low 
intervention coverage.
Information not available to ECDC or the EMCDDA. 
(i)  Based on rates of newly diagnosed HIV infections with injecting drug use as mode of transmission per 100 000 general population. Source: ECDC, The 
European Surveillance System. 2013 HIV surveillance data are still preliminary and reporting delays are likely.
(ii)  A cut-off of 30 % opioid substitution treatment coverage was used in order to limit the alert to the lowest range and likely highest HIV risk. Coverage levels 
below 50 % of the target population are considered sub-optimal.
(iii)  Syringes given out by specialised needle and syringe programmes, not including pharmacy sales. Distribution of less than 100 syringes per injecting drug 
user represents low coverage (UNAIDS 2012,Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for 
injecting drug users, 2012 revision. http://www.who.int/hiv/pub/idu/targets_universal_access/en/index.html). 
NB: HIV prevalence data for 2013, except for France (2012). HCV data for 2013, except for Austria (2008–13).
More information is available from www.emcdda.europa.eu/publications/edr/trends-developments/2015/hiv-supplementary-table
Source: For estimates of HIV and HCV prevalence, number of opioid substitution treatment clients, number of syringes provided, and estimated size of injecting 
drug user and problem opioid user populations, EMCDDA Statistical Bulletin 2015.
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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